Abstract

Metastatic colorectal cancer (mCRC) remains the third leading cause of cancer-related deaths worldwide. Wild-type (WT) K-RAS status is a major determinant for the efficacy of anti-EGFR therapy; however, as many as 40-60% patients (pts) even with this genetic background do not benefit from these regimens. While circulating cell-free miRNAs (cf-miRNAs) have emerged as an important class of cancer biomarkers, reent data suggests that miRNAs within the tumor-derived exosomal cargo (exo-miRNAs) might offer higher cancer specificity.

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call